BACKGROUND: Tissue plasminogen activator (tPA) treatment for acute ischaemic stroke (AIS) should be given as soon as possible, preferably within 60 min after arrival at hospital. There is great variation in door-to-needle times (DNTs) internationally, nationally and even within the same hospital. Various strategies for improving treatment delays have been presented. The role of emergency physicians (EPs) in treating AIS has been under discussion in recent years. Emergency Medicine (EM) officially became a specialty in Finland in 2013. Practical education of EPs in Kanta-Häme Central Hospital began in October 2012, together with reorganization of the in-hospital treatment path for AIS patients. The main change was shifting the on-call dut...
Background: The need for rapid evaluation and treatment of acute stroke patients has been well docum...
BACKGROUND AND AIMS: The short time window is frequently cited as the main reason for exclusion of i...
Explaining the risks and benefits of recombinant tissue-plasminogen activator (rtPA) to eligible pat...
BACKGROUND: Tissue plasminogen activator (tPA) treatment for acute ischaemic stroke (AIS) should ...
Objective: Ischemic strokes cause significant morbidity and mortality. Treatment with tissue plasmin...
BACKGROUND AND PURPOSE: Intravenous thrombolysis is a well-established treatment for acute ischemic ...
Despite international consensus on the benefits of thrombolysis for ischaemic stroke (IS), it remain...
BACKGROUND: The actions and responses of the hospital personnel during acute stroke care in the emer...
Objective: To assess the effectiveness of the PAST (Pre-hospital Acute Stroke Triage) protocol in re...
Background: Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is licensed f...
SUMMARY – Acute stroke is the leading cause of disability in modern society. Early treatment is cruc...
BACKGROUND AND AIMS: Thrombolytic therapy with intravenous recombinant tissue plasminogen activator...
BACKGROUND AND PURPOSE: To maximize the benefits of thrombolysis, it is necessary not only to treat ...
Background and Purpose—To maximize the benefits of thrombolysis, it is necessary not only to treat m...
To determine whether utilization of emergency medical service (EMS) can increase use and expedite de...
Background: The need for rapid evaluation and treatment of acute stroke patients has been well docum...
BACKGROUND AND AIMS: The short time window is frequently cited as the main reason for exclusion of i...
Explaining the risks and benefits of recombinant tissue-plasminogen activator (rtPA) to eligible pat...
BACKGROUND: Tissue plasminogen activator (tPA) treatment for acute ischaemic stroke (AIS) should ...
Objective: Ischemic strokes cause significant morbidity and mortality. Treatment with tissue plasmin...
BACKGROUND AND PURPOSE: Intravenous thrombolysis is a well-established treatment for acute ischemic ...
Despite international consensus on the benefits of thrombolysis for ischaemic stroke (IS), it remain...
BACKGROUND: The actions and responses of the hospital personnel during acute stroke care in the emer...
Objective: To assess the effectiveness of the PAST (Pre-hospital Acute Stroke Triage) protocol in re...
Background: Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is licensed f...
SUMMARY – Acute stroke is the leading cause of disability in modern society. Early treatment is cruc...
BACKGROUND AND AIMS: Thrombolytic therapy with intravenous recombinant tissue plasminogen activator...
BACKGROUND AND PURPOSE: To maximize the benefits of thrombolysis, it is necessary not only to treat ...
Background and Purpose—To maximize the benefits of thrombolysis, it is necessary not only to treat m...
To determine whether utilization of emergency medical service (EMS) can increase use and expedite de...
Background: The need for rapid evaluation and treatment of acute stroke patients has been well docum...
BACKGROUND AND AIMS: The short time window is frequently cited as the main reason for exclusion of i...
Explaining the risks and benefits of recombinant tissue-plasminogen activator (rtPA) to eligible pat...